Some of us here don't post much but we are AMBS MB
Post# of 30029
Posted On: 04/02/2015 1:06:34 PM
Some of us here don't post much but we are AMBS MB members. The constant news of what the "Private Board" members are doing is annoying at the least and is not relevant to AMBS discussion.
Clearly us quieter members who post little due to the historical nature of being attacked when we do were of no value to the departing members.
So please stop providing us the updates.
BTW, the ESS-W option extension is being used to get the Phase1/Pahse2 trials prepared.
Qoute
"Part of the proceeds from the option fees paid by the Company will be used by Lonza to prepare for a Phase 1/Early Phase 2
clinical trial of Engineered Skin Substitute Walkersville (“ESS-W”).
During the option period, the Company shall assist Lonza with the project management of the ESS-W program and Lonza shall
provide the Company access to certain documents related to obtaining approval of an Institutional Review Board at the clinical site(s), initially a U.S. Military clinical site."
This is positive news and pretty much overlooked by everyone.
ESS-W has been held up by the lawsuit for many years. Gerald tweeted this link https://clinicaltrials.gov/ct2/show/NCT01655407 which outlines the trial that was originally planned to be started in 2012.
There should be no complaining about the option extension if you are a true long...
Clearly us quieter members who post little due to the historical nature of being attacked when we do were of no value to the departing members.
So please stop providing us the updates.
BTW, the ESS-W option extension is being used to get the Phase1/Pahse2 trials prepared.
Qoute
"Part of the proceeds from the option fees paid by the Company will be used by Lonza to prepare for a Phase 1/Early Phase 2
clinical trial of Engineered Skin Substitute Walkersville (“ESS-W”).
During the option period, the Company shall assist Lonza with the project management of the ESS-W program and Lonza shall
provide the Company access to certain documents related to obtaining approval of an Institutional Review Board at the clinical site(s), initially a U.S. Military clinical site."
This is positive news and pretty much overlooked by everyone.
ESS-W has been held up by the lawsuit for many years. Gerald tweeted this link https://clinicaltrials.gov/ct2/show/NCT01655407 which outlines the trial that was originally planned to be started in 2012.
There should be no complaining about the option extension if you are a true long...
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼